Cargando…
Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients’ preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966566/ https://www.ncbi.nlm.nih.gov/pubmed/27524889 http://dx.doi.org/10.2147/PPA.S109289 |
_version_ | 1782445396758364160 |
---|---|
author | Gelhorn, Heather L Bacci, Elizabeth D Poon, Jiat Ling Boye, Kristina S Suzuki, Shuichi Babineaux, Steven M |
author_facet | Gelhorn, Heather L Bacci, Elizabeth D Poon, Jiat Ling Boye, Kristina S Suzuki, Shuichi Babineaux, Steven M |
author_sort | Gelhorn, Heather L |
collection | PubMed |
description | OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients’ preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. METHODS: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: “dosing frequency”, “hemoglobin A1c change”, “weight change”, “type of delivery system”, “frequency of nausea”, and “frequency of hypoglycemia”. Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. RESULTS: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation =10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation =5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). CONCLUSION: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients’ preferences that may be informative for patient–clinician treatment discussions. |
format | Online Article Text |
id | pubmed-4966566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49665662016-08-12 Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan Gelhorn, Heather L Bacci, Elizabeth D Poon, Jiat Ling Boye, Kristina S Suzuki, Shuichi Babineaux, Steven M Patient Prefer Adherence Original Research OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients’ preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. METHODS: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: “dosing frequency”, “hemoglobin A1c change”, “weight change”, “type of delivery system”, “frequency of nausea”, and “frequency of hypoglycemia”. Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. RESULTS: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation =10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation =5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). CONCLUSION: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients’ preferences that may be informative for patient–clinician treatment discussions. Dove Medical Press 2016-07-25 /pmc/articles/PMC4966566/ /pubmed/27524889 http://dx.doi.org/10.2147/PPA.S109289 Text en © 2016 Gelhorn et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Gelhorn, Heather L Bacci, Elizabeth D Poon, Jiat Ling Boye, Kristina S Suzuki, Shuichi Babineaux, Steven M Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan |
title | Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan |
title_full | Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan |
title_fullStr | Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan |
title_full_unstemmed | Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan |
title_short | Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan |
title_sort | evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in japan |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966566/ https://www.ncbi.nlm.nih.gov/pubmed/27524889 http://dx.doi.org/10.2147/PPA.S109289 |
work_keys_str_mv | AT gelhornheatherl evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan AT baccielizabethd evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan AT poonjiatling evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan AT boyekristinas evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan AT suzukishuichi evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan AT babineauxstevenm evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan |